The novel human gene family encoding neuronal leucine rich repeat (NLRR) proteins were identified as prognostic markers from our previous screening of primary neuroblastoma (NB) cDNA libraries. Of the NLRR gene family members, NLRR1 and NLRR3 are associated with the regulation of cellular proliferation and differentiation, respectively. However, the functional regulation and clinical significance of NLRR2 in NB remain unclear. Here, we evaluated the differential expression of NLRR2, where high expressions of NLRR2 were significantly associated with a poor prognosis of NB (P = 0.0009), in 78 NBs. Enforced expression of NLRR2 in NB cells enhanced cellular proliferation and induced resistance to retinoic acid (RA)-mediated cell growth inhibition. In contrast, knockdown of NLRR2 exhibited growth inhibition effects and enhanced RA-induced cell differentiation in NB cells. After RA treatment, NLRR2 expression was increased and correlated with the upregulation of c-Jun, a member of the activator protein-1 (AP-1) family in NB cells. Moreover, the expressions of NLRR2 and c-Jun were suppressed by treatment with a JNK inhibitor, which ameliorated the promoter activity of the NLRR2 gene while knockdown of c-Jun reduced NLRR2 expression. We then searched AP-1 binding consensus in the NLRR2 promoter region and confirmed c-Jun recruitment at a consensus. Conclusively, NLRR2 must be an inducible gene regulated by the JNK pathway to enhance cell survival and inhibit NB cell differentiation. Therefore, NLRR2 should have an important role in NB aggressiveness and be a potential therapeutic target for the treatment of RA resistant and aggressive NB.
The novel human gene family encoding neuronal leucine rich repeat (NLRR) proteins were identified as prognostic markers from our previous screening of primary neuroblastoma (NB) cDNA libraries. Of the NLRR gene family members, NLRR1 and NLRR3 are associated with the regulation of cellular proliferation and differentiation, respectively. However, the functional regulation and clinical significance of NLRR2 in NB remain unclear. Here, we evaluated the differential expression of NLRR2, where high expressions of NLRR2 were significantly associated with a poor prognosis of NB (P = 0.0009), in 78 NBs. Enforced expression of NLRR2 in NB cells enhanced cellular proliferation and induced resistance to retinoic acid (RA)-mediated cell growth inhibition. In contrast, knockdown of NLRR2 exhibited growth inhibition effects and enhanced RA-induced cell differentiation in NB cells. After RA treatment, NLRR2 expression was increased and correlated with the upregulation of c-Jun, a member of the activator protein-1 (AP-1) family in NB cells. Moreover, the expressions of NLRR2 and c-Jun were suppressed by treatment with a JNK inhibitor, which ameliorated the promoter activity of the NLRR2 gene while knockdown of c-Jun reduced NLRR2 expression. We then searched AP-1 binding consensus in the NLRR2 promoter region and confirmed c-Jun recruitment at a consensus. Conclusively, NLRR2 must be an inducible gene regulated by the JNK pathway to enhance cell survival and inhibit NB cell differentiation. Therefore, NLRR2 should have an important role in NB aggressiveness and be a potential therapeutic target for the treatment of RA resistant and aggressive NB. N euroblastoma (NB) is the most common form of malignancy in early childhood and is derived from the sympathoadrenal lineage of neural crest progenitor cells.
(1) NB exerts heterogeneous clinical behavior. Some NB regress spontaneously while others progress to highly metastatic tumors with a poor prognosis despite intensive multimodal therapy. (2) However, the pathogenesis of NB is poorly understood as very few gene defects have been identified in this often-lethal tumor. Frequently detected genetic alterations of NB are limited to MYCN amplification and ALK activation. (3) (4) (5) Hence, aberrant gene expression patterns have been shown to be important to identify mechanisms behind the clinical outcome of NB. For example, high expression of the neurotrophic receptor TrkA has been identified as a prognostic factor for a favorable outcome because it inhibits tumor growth and angiogenesis, whereas TrkB and its ligand, brain-derived neurotrophic factor, are associated with aggressive NB with MYCN amplification that enhances tumor growth and angiogenesis. (4, (6) (7) (8) Some factors related to NB pathogenesis are involved in proliferation, differentiation and metastasis. However, little is known about their biological function with regards to tumor growth aggressiveness and this has negatively impacted on the development of therapeutic drugs. Therefore, studies on the molecular mechanisms of NB are required to develop new therapeutic strategies to treat aggressive NB.
Retinoic acid is an important metabolite that functions as a morphogen in the developing nervous system in vivo and induces the differentiation of neuronal cells in vitro. (9) It has been implicated in human NB because RA treatment inhibits NB proliferation, differentiates into neuronal-like cells, and reduces cell migration and invasiveness. (10) (11) (12) (13) These properties have been used as a basis for the clinical application of RA, one of the limited drugs currently used to treat this type of cancer. (10) (11) (12) (13) (14) It has become standard practice to treat high-risk NB patients after marrow or stem cell transplantation. (15) However, despite multiple clinical efforts, the prognosis remains poor for this enigmatic disease because of the high rate of resistance and metastasis. Human NB cells also often express multidrug resistance genes during differentiation by RA treatment. (16, 17) Therefore, to overcome drug resistance in the aggressive NB, it is important to identify factors that contribute to RA resistant and RA-mediated NB cell differentiation. RA binds to RAR and activates a signal transduction pathway that involves multiple cytoplasmic signaling molecules such as JNK and ERK. The JNK pathway has been proposed to induce a signaling cascade during RA-mediated differentiation of NB as well as non-NB. (18) (19) (20) The downstream component of JNK/SAP MAPK is activator protein-1 (AP-1), which is a homodimeric or heterodimeric complex consisting of c-Jun, c-fos, Maf and ATF2. Based on the cellular context, the composition of the AP-1 dimeric complex determines its functions in the regulation of differentiation, proliferation and apoptosis. (19) (20) (21) (22) (23) However, the direct molecular mediator in transmitting RA signal to regulate neuritis extension in NB has remained unknown. Here, we report that NLRR2 acts as an inhibitor for the RA-mediated differentiation of NB, and, therefore, contributes to NB aggressiveness.
NLRR2 is a member of the NLRR gene family that encode a glycosylated transmembrane protein with a leucine rich repeat (LRR) domain containing 11 or 12 LRR, an immunoglobulin c2-type domain, and a type III fibronectin domain in its extracellular domain. Like other NLRR family proteins, NLRR2 has highly conserved amino acid sequences in the extracellular domain, which includes substrate/chemical binding sites and four potential glycosylation sites. NLRR2 also possesses ww interacting domains in the short intracellular region, which mediate protein-protein interactions and might provide a basis of signaling events for NLRR function in tumorigenesis. (24) (25) (26) We previously reported that NLRR1 enhances epidermal growth factor (EGF)-mediated MYCN induction in NB, resulting in the acceleration of tumor growth in vivo, and that a high expression of NLRR1 mRNA levels is associated with a poor prognosis of NB. In contrast, low NLRR3 expression levels were correlated with a poor prognosis in NB patients. (27) (28) (29) However, very little is known about the role of NLRR2 in tumor progression, except it has been reported to be amplified and overexpressed in malignant gliomas. (30) The current study reveals that RA functions as a negative feedback regulator through the upregulation of NLRR2 during RA-mediated differentiation in NB. NLRR2 might be a useful pharmacological indicator to predict RA efficiency in NB treatment and should be considered as a therapeutic target for RA-resistant aggressive NB.
Materials and Methods
Cell culture and agents. Human NB-derived TGW, SMS-SAN and non-NB HeLa cells were collected from The Children's Hospital of Philadelphia cell line bank (Philadelphia, PA, USA), and SK-N-BE NB cells were collected from the European Collection of Cell Cultures (Wiltshire, UK) cell bank. NB cells were maintained in RPMI 1640 medium (Wako, Osaka, Japan), supplemented with 10% heatinactivated FBS (Invitrogen, CA, USA), 50 lg/mL penicillin and 50 lg/mL streptomycin (Invitrogen). HeLa cells were maintained in DMEM medium (Wako) with the same supplements. All cells were cultured in a humidified chamber provided with 5% CO 2 ) was used to target human NLRR2 (Takara, Shiga, Japan). c-Jun siRNA was purchased from Cell Signaling Technology (#6203; Boston, MA, USA) and Santa Cruz Biotechnology (sc-29223; Dallas, TX, USA). Control non-targeting siRNA was purchased from Thermo Fisher Scientific (Waltham, MA, USA). NB cells were transfected with siRNA by forward-transfection according to the manufacturer's protocol using Lipofectamine RNAiMAX reagent (Invitrogen). We used siRNA (concentration 50 nM) for siNLRR2 and 100 nM for sic-Jun because these concentrations worked well in a preliminary study (Fig. S1 ).
In vivo tumorigenicity assays. SK-N-BE cells at a density of 1 9 10 7 were inoculated s.c. into 7-week-old female SCID mice. One week after inoculation, when the tumors had an average volume of 70 AE 30 mm 3 , a mixture of 1 nmol of control or a mixture of two sets of NLRR2 siRNA and 200 lL of atelocollagen (Koken, Tokyo, Japan) was injected to the site of the tumor to evaluate the growth inhibition effect. Animal experiments were performed in compliance with the regulations for animal experiments of IACUC (IACUC approved # 15-4).
Statistical analysis. Results were shown as the mean AE SD. Student's t-test was used to compare the differences in means between two groups. The difference between groups was evaluated by repeated measures ANOVA followed by Bonferroni post-test. P < 0.05 was considered statistically significant.
More detailed descriptions of the material and methods are described in Appendix S1.
Results
Expression of NLRR2 is associated with the poor prognosis of neuroblastoma and enhances oncogenic transformation in vitro and in vivo. Previously, we identified NLRR family genes which are differentially expressed between favorable and unfavorable NB from the screening of nearly 2000 genes using our unique NB cDNA libraries. Human NLRR2 is a highly expressed gene in NB-derived cell lines (26) and may be used to define clinical relevancies of NB. We performed gene expression analysis by real-time PCR using NB cDNA from 7 SK-N-BE cells. Two weeks after inoculation, when the tumors had an average volume of 70 AE 30 mm 3 , 1 nmol of control siRNA or a mixture of two siNLRR2 siRNA with 200 lL of atelocollagen was injected to the tumor mass to evaluate the growth inhibition effect. In vivo knockdown efficiency was measured by quantitative PCR (g). siNLRR2 treatment significantly (**P < 0.01) reduced the tumor growth compared with the control siRNA-treated group (h). (i, j) Four weeks after treatment, the tumors were removed (i). The tumor weight was significantly (**P < 0.01) reduced in the siNLRR2-treated group compared with the control siRNA group (j). 78 patients. Kaplan-Meier survival curves indicated that NB with high NLRR2 expression significantly associated with a poor clinical prognosis (P < 0.001) (Fig. 1a) . A Kaplan-Meier survival analysis using a public R2 microarray dataset from 88 NB patients (http://r2.amc.nl) also revealed that high expression of NLRR2 was associated with worse overall survival and relapse-free NB outcome (Fig. S2) To investigate the oncogenic effect of NLRR2 in NB, we stably or transiently expressed NLRR2 in SK-N-BE cells that resulted in significant increase of proliferation compared with the mock control cells (Fig. 1b,c) . Overexpression of NLRR2 also resulted in a significant increase of cell proliferation in SMS-SAN cells (Fig. 1d) . In addition, the downregulation of NLRR2 by siRNA-mediated knockdown significantly (P < 0.01) reduced the cell growth in SK-N-BE and SMS-SAN cells (Fig. 1e,f) . To confirm the function of NLRR2 in vivo, we locally treated mice bearing tumors derived from SK-N-BE cells with atelocollagen complexed with siNLRR2 (Fig. 1g) . Compared with the control siRNA group, siNLRR2 treatment significantly reduced the tumor growth of SK-N-BE xenograft tumors (Fig. 1h,i and j) . These data suggest that the function of NLRR2 is involved in tumorigenesis and is associated with a poor prognosis of NB.
NLRR2 inhibits differentiation in neuroblastoma cells. We investigated whether or not NLRR2 has a function in cell growth and differentiation processes of NB. The transfection of siNLRR2 had no effect on the expression levels of other family genes, NLRR1 and NLRR3 (Fig. 2a) . After transfection of siNLRR2, the growth of SK-N-BE cells was significantly repressed by RA treatment (Fig. 2b) . Interestingly, the differentiation data revealed that NLRR2-knockdown cells were more susceptible to RA-mediated differentiation (Fig. 2c,d ). The enhanced cell differentiation by NLRR2 knockdown was confirmed by higher levels of GAP43 and NF-M, (31) (32) (33) neuronal differentiation markers (Fig. 2e) . These data suggest that NLRR2 knockdown retards cell growth and enhances cell differentiation induced by RA treatment.
c-Jun is important for the regulation of NLRR2 expression. We next examined NLRR2 expression during RA-induced differentiation (Fig. S3 ) of NB cells. Interestingly, mRNA and protein levels of NLRR2 expression were elevated in RA-treated NB cells (Fig. 3a,b) . Consistent with previous reports showing the RA-mediated induction of c-Jun, (18, 19, 34) c-Jun expression in NB cells was also increased upon RA treatment, whereas expressions of other AP-1 members, such as c-fos and ATF-2, were reduced (Fig. S4) . To investigate whether c-Jun was important for the regulation of NLRR2 expression, NB cells were transiently transfected with c-Jun siRNA, resulting in reduced expressions of NLRR2 mRNA (Figs 3c,d and S1) and protein (Fig. 3e) . Because RA treatment failed to rescue the NLRR2 expression in c-Jun knockdown cells, these data demonstrated that c-Jun functions by regulating RA-induced NLRR2 expression. NLRR2 gene, we generated luciferase reporter constructs containing À790 bp to +110 bp fragments of the NLRR2 gene where +1 represents the transcriptional initiation site. We performed a promoter assay in HeLa cells because they have high transfection efficiency. RA-treatment also induced NLRR2 and c-Jun expression in HeLa cells (Fig. S5) . The promoter activity determined by luciferase reporter analysis was increased in response to RA treatment (Fig. 4a) . The study using a series of deletion mutants of the promoter constructs showed that the luciferase activity was highest in between the À790 and À560 region, which contains a c-Jun binding site of TPA-responsive element (TRE), TGACAAA. We confirmed similar luciferase activity data in SK-N-BE cells (Fig. 4b) using a À790 to +110 promoter construct including an AP-1 binding site. Next, we performed a ChIP assay to determine whether c-Jun directly binds to the promoter region of NLRR2. As shown in Figure 4c , the recruitment of c-Jun to the NLRR2 promoter was increased by RA treatment, indicating that NLRR2 is transcriptionally regulated by c-Jun.
NLRR2 expression is regulated by the JNK pathway. NLRR2 promoter activity was suppressed in SK-N-BE cells following treatment with a JNK inhibitor (Fig. 5a ). To confirm that NLRR2 is regulated through the JNK pathway, we treated TGW and SK-N-BE cells with a JNK inhibitor to examine the expression of NLRR2. As expected, JNK inhibition reduced the expression of NLRR2 and c-Jun at both the mRNA and protein levels (Fig. 5b,c) , although NLRR2 induction upon RA treatment was marginally reduced by JNK inhibition (Fig. S6) . To confirm the function of the JNK pathway in the regulation of NLRR2 expression, we used sorbitol, which induces JNK activation. (35, 36) The phosphorylation of JNK and c-Jun as well as the expression of NLRR2 were induced by sorbitol treatment in SK-N-BE cells and co-treatment with a JNK inhibitor ameliorated the induction of NLRR2 expression (Fig. 5d,e) . Thus, the JNK pathway is particularly important for regulating NLRR2 expression in NB cells.
NLRR2 exhibits survival to retinoic acid and other stress-mediating agents in neuroblastoma cells. Because the JNK pathway was induced by not only RA but the other agents such as sorbitol, we next treated NB cells with a DNA-damaging agent that causes cellular stress. The treatment of cisplatin (CDDP) showed a clear induction of NLRR2 expression in SMS-SAN cells and the smaller induction was observed in SK-N-BE cells (Figs 6a and S7 ). To examine whether NLRR2 expression was associated with cell survival against cellular stress, NLRR2-stably expressing cells were treated with RA and cell viability was examined. As shown in Figure 6b , NLRR2-stable cells were significantly resistant to RA treatment compared with the mock stable cell control. In contrast, NLRR2 knockdown cells showed significant susceptibility to CDDP treatment (Fig. S8) . These data suggest that the cellular stress responses and NLRR2 induction vary more or less depending on the types of agents and cell lines. Next, we checked the morphology of the NLRR2 stable and mock cells upon RA treatment to study the differentiation function of NLRR2. The data showed that the stable expression of NLRR2 significantly (P < 0.01) inhibited RA-induced differentiation compared with controls (Fig. S9) . Therefore, after the induction of NLRR2 by cellular stressmediating agents, NLRR2, in turn, reduced cytotoxicity of NB cells.
JNK inhibition in neuroblastoma cells overexpressing NLRR2
rescues resistance to retinoic acid and induces differentiation. To further confirm the functional regulation of NLRR2 through JNK pathway, RA treatment was given to NLRR2 overexpressing cells with or without prior JNK inhibitor treatment. Data demonstrated that JNK inhibition in NLRR2 overexpressing cells rescued the resistance phenotype (Fig. 7a) and also induced significant differentiation to RA treatment (Fig. 7b,c) . The expression of NLRR2, phospho-c-Jun and c-Jun were suppressed by JNK inhibition (Fig. 7d ) in NLRR2 overexpressing NB cells.
Discussion
Our results clearly demonstrate the clinical relevance of NLRR2 expression and its functional role in RA-induced cell differentiation. NLRR2 enhances the cell survival of RAtreated NB cells, while other family members, NLRR1 and NLRR3, are associated with cell proliferation and differentiation. (28, 29) In addition, mouse NLRR3 was reported to modulate MAPK signaling through the EGFR pathway, (35) indicating that each NLRR family protein might have functional relevance in cell signaling events. The present study suggests that the high expression of NLRR2 is significantly associated with the poor prognosis of NB, consistent with data analyzed using an R2 platform suggesting that NLRR2 serves as a prognostic marker of NB. Of note, a similar observation was reported for malignant gliomas. (30) The local treatment of siNLRR2 in a mouse xenograft model of NB significantly reduced tumor growth, suggesting that the low expression of NLRR2 solely restricts tumor progression. Further study may clarify the clinical significance of NLRR2 expression in tumorigenesis.
Our in vitro experiments that modulated the expression of NLRR2 in NB cells indicated the potential molecular mechanisms of how NLRR2 might be involved in the poor clinical outcome of NB (Fig. 8) . NLRR2-overexpressing cells showed the enhanced cell proliferation and significant resistance phenotype to RA treatment. In contrast, NLRR2 knockdown cells were more susceptible to RA-mediated cell growth inhibition and exhibited significantly increased numbers of differentiated cells compared with control cells. Even a 50% reduction of NLRR2 expression by siNLRR2 was enough to show these significant results. These data suggest that the function of NLRR2 is to inhibit the differentiation process and support the cell survival of RA-treated cells. Retinoic acid is a potent differentiation inducer of NB cells and causes a marked suppression of MYCN expression. (29, 36, 37) However, our previous observation has demonstrated that NLRR2 expression is not correlated with MYCN expression (data not shown), while NLRR1 positively regulates cellular proliferation through MYCN induction and NLRR3 is negatively regulated by MYCN to facilitate differentiation of NB cells. (28, 29) In the present study, we found that c-Jun plays a key role in regulating NLRR2 gene expression in RA-treated NB cells. RA-treated NB cells exhibited the co-induction of NLRR2 and c-Jun. The activity of JNK appears to be important for the induction of NLRR2, which is consistent with previous reports regarding the induction and activation of c-Jun downstream of the JNK pathway after RA treatment. (19, 20) It is noteworthy that a DNA damaging agent, CDDP, also induced NLRR2 in NB cells. The significant survival difference observed in the clinical subsets with low and high expressions of NLRR2 may be explained by the stress-induced upregulation of NLRR2, which, in turn, contributes to the drug resistance of NB cells. An anti-apoptotic role of activated c-Jun/ AP-1 transcription factor was reported to protect human tumor cells from DNA-damaging agents. (38) Thus, the effects observed in this study suggest that activated AP-1 complexes exert a favorable influence on cell survival that counters diverse external stresses induced by drugs.
Although the JNK and p38MAPK pathways can potentially synergize to induce AP-1 transcriptional activity and share cJun as a common substrate, (39) we found a limited effect of p38MAPK inhibition on RA-induced differentiation as well as NLRR2 expression in NB cells (data not shown). There is considerable evidence that neurite outgrowth stimulated by RA is partially dependent on JNK activity. (18) c-Jun/AP-1 was reported to be involved in neuronal differentiation and protection from apoptosis in NB cells. (40) However, the relevant functions and target genes of AP-1 in neuronal differentiation have not been elucidated yet. In particular, it is unclear whether AP-1 in NB cells facilitates cell death or, conversely, is part of a protective response against differentiation or apoptosis. Our experimental evidence suggests that c-Jun/AP-1 in RA-treated NB cells plays a protective role by upregulating the expression of NLRR2. Future studies might explain why the prognosis of NB treated with RA remains poor, with a high rate of resistance and metastasis. (16, 17) The present study indicates the clinical relevance of NLRR2 and a regulatory mechanism of NLRR2 transcription in RAtreated NB cells. The expression of NLRR2 is transcriptionally regulated by the JNK-c-Jun axis and enhances cell survival in drug-treated NB cells. Therefore, NLRR2 might be a key target molecule for the development of new therapeutic strategies to overcome RA resistance in aggressive NLRR2-expressing NB.
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